BioSpace News Archive

Origin Agritech Ltd. announced that the Company has entered into a collaboration agreement with Biotechnology Research Institute of Chinese Academy of Agriculture Sciences to speed up the commercialization of genetically modified insect resistance and glyphosate tolerance corn traits in China.

Lipocine Inc. announced that the U.S. District Court of Delaware has set a trial date for Lipocine’s patent infringement lawsuit against Clarus’s JATENZO® drug product relating to six of Lipocine’s U.S. patents.

Presage Biosciences announced it has entered into a research collaboration with Bristol-Myers Squibb Company to evaluate early stage oncology targets in Phase 0 trials.

Angel MedFlight Worldwide Air Ambulance will be a featured VMware customer partner at the VMworld 2019 conference, August 25-29 in San Francisco, California.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for AtriClip® LAA management devices, including changing the indication from occlusion of the LAA to exclusion, and also adding electrical isolation as a labeling claim

Celsius Holdings, Inc. (Nasdaq: CELH), maker of the leading global fitness drink, CELSIUS®, today announced that the company is expanding its product portfolio to include an innovative branched-chain amino acids (BCAA) functional beverage that fuels muscle recovery

SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), and Enteris BioPharma, Inc. (“Enteris”), a biotechnology company offering innovative formulation solutions utilizing its proprietary oral drug delivery technology, Peptelligence®, announced today a strategic acquisition whereby SWK, through its wholly-owned subsidiary, SWK Acquisition Corporation, has acquired 100% of Enteris’ equity from Victory Park Capital (“Seller”).

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.

Primary PartnerCare ACO Independent Practice Association, Inc and Primary PartnerCare Management Group, Inc. announced the results of a research study correlating the frequency of Hemoglobin A1c testing and the hospitalization rate and costs for diabetic patients.

Net Sales of $134 Million Exceeds Expectations